ArticleJournal of orthopaedic translation2026
TRIM59 alleviates neuronal ferroptosis and promotes functional recovery after spinal cord injury by mediating ubiquitination and degradation of ANXA2.
Article in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating mechanistic research and emerging technologies to advance clinical translation in orthopaedics.Journal of orthopaedic translation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spinal cord injury (SCI) is a severe central nervous system disorder for which effective therapeutic interventions remain limited. Accumulating evidence indicates that ferroptosis is a key contributor to secondary neuronal damage following SCI, yet its upstream regulators-particularly those involving post-translational modifications such as ubiquitination-remain incompletely understood. This study aimed to determine whether the E3 ubiquitin ligase TRIM59 modulates neuronal ferroptosis and functional recovery after SCI, and to elucidate its molecular substrate and underlying mechanism of action. Methods: TRIM59 expression was modulated using lentiviral vectors in cultured neurons and adeno-associated virus serotype 9 (AAV9) in mice. Functional recovery was assessed through the BMS, inclined plane test, footprint analysis, and motor evoked potentials. Ferroptosis was evaluated via biochemical assays, BODIPY C11 staining, ROS detection, TEM, and ferroptosis markers. Molecular interactions were analyzed by co-immunoprecipitation (Co-IP), ubiquitination assays, and cycloheximide (CHX) chase experiment. Results: TRIM59 expression was significantly downregulated during Erastin-induced ferroptosis in neurons and in spinal cord tissue during the acute phase (days 1-3) after SCI. Downregulation of TRIM59 exacerbated the hallmark features of ferroptosis and impaired motor recovery, whereas TRIM59 overexpression attenuated ferroptosis and promoted neurological restoration. Mechanistically, TRIM59 directly bound to ANXA2 and mediated its K48-linked polyubiquitination and subsequent proteasomal degradation. The neuroprotective effect of TRIM59 was abolished by a catalytically inactive C30A mutant or by ANXA2 overexpression, whereas ANXA2 knockdown rescued the ferroptosis and functional deficits induced by TRIM59 deficiency. Conclusion: This study identifies a novel TRIM59-ANXA2 regulatory axis that critically governs neuronal ferroptosis and functional recovery after SCI. TRIM59 functions as an endogenous suppressor of ferroptosis by targeting ANXA2 for K48-linked ubiquitin-proteasome-mediated degradation. These findings not only elucidate a key post-translational mechanism in SCI pathophysiology but also position TRIM59 as a promising therapeutic target for neuroprotection and functional restoration following SCI. The translational potential of this article: Targeting the TRIM59-ANXA2 pathway offers a promising therapeutic strategy to inhibit ferroptosis and promote neuroprotection and functional recovery after SCI. Enhancing TRIM59 activity or disrupting ANXA2 stability could pave the way for novel treatments in clinical neurotrauma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.